[{"id":"0f9bc919-4e69-4675-bc62-35e94a94fa58","acronym":"INT22-09-01","url":"https://clinicaltrials.gov/study/NCT05521698","created_at":"2022-08-30T20:56:03.144Z","updated_at":"2025-02-25T13:41:12.118Z","phase":"Phase 1","brief_title":"Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT05521698 - INT22-09-01","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/23/2025","start_date":" 04/23/2025","primary_txt":" Primary completion: 01/15/2027","primary_completion_date":" 01/15/2027","study_txt":" Completion: 07/15/2027","study_completion_date":" 07/15/2027","last_update_posted":"2025-02-21"}]